Vimarsana
Biggest News Aggregation in the World

Page 11 - Altimmune News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Altimmune. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Altimmune Today - Breaking & Trending Today

Altimmune's (ALT) Market Outperform Rating Reiterated at JMP Securities - Vimarsana News

Altimmune's (ALT) Market Outperform Rating Reiterated at JMP Securities

JMP Securities reissued their market outperform rating on shares of Altimmune (NASDAQ:ALT – Get Rating) in a report published on Wednesday morning, Benzinga reports. JMP Securities currently has a $26.00 target price on the stock. Other analysts also recently issued reports about the stock. Evercore ISI lifted their price objective on shares of Altimmune from […]

Matthew Scott Harris Purchases 10,000 Shares of Altimmune, Inc. (NASDAQ:ALT) Stock - Vimarsana News

Matthew Scott Harris Purchases 10,000 Shares of Altimmune, Inc. (NASDAQ:ALT) Stock

Altimmune, Inc. (NASDAQ:ALT – Get Rating) insider Matthew Scott Harris bought 10,000 shares of the stock in a transaction on Thursday, March 23rd. The shares were acquired at an average cost of $4.22 per share, for a total transaction of $42,200.00. Following the purchase, the insider now owns 33,311 shares in the company, valued at […]

Altimmune (NASDAQ:ALT) Cut to Neutral at The Goldman Sachs Group - Vimarsana News

Altimmune (NASDAQ:ALT) Cut to Neutral at The Goldman Sachs Group

The Goldman Sachs Group cut shares of Altimmune (NASDAQ:ALT – Get Rating) from a buy rating to a neutral rating in a research report report published on Tuesday, MarketBeat reports. The brokerage currently has $6.00 price objective on the stock, down from their prior price objective of $20.00. A number of other equities research analysts […]

Altimmune Stock Tanks 50% After Releasing Phase 2 Trial Data Of Obesity Drug - Vimarsana News

Altimmune Stock Tanks 50% After Releasing Phase 2 Trial Data Of Obesity Drug

Shares of Altimmune, Inc. (ALT) tanked over 50% on Tuesday morning after the company released phase 2 trial data of obesity drug pemvidutide. ALT is currently trading at $5.

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming EASL International Liver Congress™ on June 25, 2022 - Vimarsana News

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming EASL International Liver Congress™ on June 25, 2022

GAITHERSBURG, Md., June 17, 2022 -- Altimmune, Inc. , a clinical-stage biopharmaceutical company, today announced that Dr. Stephen A. Harrison, Medical Director, Pinnacle Clinical Research, will... | June 17, 2022